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Although a large superfamily of G-protein-coupled receptors serves multiple functions, little is known about their
functional activation during ontogeny. To examine the functional activation of the mu-opioid receptor (MOR) and the
delta-opioid receptor (DOR) during development, sections of mouse embryos and fetuses from e11.5 until birth were treated
with DAMGO and DPDPE, respectively, and the ability of these drugs to induce G-protein coupling was assessed by using
GTP35S binding autoradiography. MOR activation was first detected in the caudate-putamen (CPU) at e12.5, and by e15.5,
activity had not only increased in this region but also expanded to include the midbrain, medial habenula, hypothalamus,
pons, and medulla. DOR activity first appeared at e17.5 in the hypothalamus, pons, medial habenula, and medulla and at
p1 in the CPU at levels noticeably less than those of the MOR. In general, MOR and DOR activation lagged only slightly
behind the appearance of MOR-1 and DOR-1 mRNA but delayed activation was particularly pronounced in the trigeminal
ganglia, where MOR-1 gene expression was first detected at e13.5, but MOR activity was not observed even at birth. Thus,
the data demonstrate temporal and often region-specific differences in the appearance and magnitude of functional activity
in cell groups expressing either the MOR-1 or DOR-1 genes, suggesting that interaction between the opioid receptors,
G-proteins, and other signaling cofactors is developmentally regulated. © 2003 Elsevier Science (USA)
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G-protein-coupled receptors (GPCR) comprise a large
superfamily of receptors with over 1000 members discov-
ered to date. These receptors participate in the actions of a
variety of ligands, including biogenic amines, peptides,
glycoproteins, lipids, nucleotides, ions, and proteases, and
participate in the perception of external stimuli, such as
light, odor, and taste (Kolakowski, 1994; Mombaerts, 1999).
Current knowledge indicates that GPCR are involved in a
myriad of biological processes both in the CNS and
throughout the organism.
Embryonic development of the nervous system is one
process in which the involvement of GPCR warrants inves-
tigation. One group of GPCR that has received significant
attention in this context is the opioid receptor family. A
role for the opioid system in the development of both
nervous and somatic structures has been suggested based on
studies showing many detrimental effects of perinatal ex-
posure to both morphine and methadone, including lowered
survival rates (Eriksson and Ronnback, 1989; Hutchings et
al., 1992), decreased body weight (Ford and Rhines, 1979;
Eriksson and Ronnback, 1989; Kunko et al., 1996), impeded
brain growth (Zagon and McLaughlin, 1977; Ford and
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All rights reserved.Rhines, 1979), delayed appearance of neuromuscular re-
flexes and behaviors (Zagon and McLaughlin, 1978; Zagon
et al., 1979a,b; Kunko et al., 1996), restricted neuronal
proliferation (Seatriz and Hammer, 1993), and physical
dependence (Zagon and McLaughlin, 1981; Seatriz and
Hammer, 1993). Chronic administration of the general
opiate antagonist naltrexone to newborn pups or pregnant
mice was initially shown to produce several interesting
phenotypes, including increased weight, enlarged brains,
increased cerebellar volume, an acceleration in the appear-
ance of sensorimotor behaviors, and increased Purkinje cell
dendritic arborization (Zagon and McLaughlin, 1983, 1985,
1987; Zagon, 1987). More recent studies have shown that
continuous opioid receptor blockade for the duration of
gestation results in even greater increases in body, brain,
and organ growth (McLaughlin et al., 1997b), accelerates
the appearance of physical characteristics, reflexes, and
spontaneous motor behaviors (McLaughlin et al., 1997a),
and produces a decrease in MOR binding density and
decreased sensitivity to the analgesic effects of morphine
(Zagon et al., 1998).
The effect of the opioid system on development is also of
clinical interest as many human infants born to either
actively abusing or methadone-maintained heroin addicted
mothers are exposed to opiates in utero. A prospective
study of human opiate-exposed infants revealed that at 1
99
year postnatally these children are at an increased risk for
mild impairment in psychomotor development (Buni-
kowski et al., 1998). Understanding how the opioid recep-
tors function during the fetal period will thus be useful in
assessing the mechanism by which in utero opiates produce
these and other negative outcomes.
The region-specific appearance of messenger RNA for the
three classical opioid receptors (MOR-1, DOR-1, and
KOR-1) has been described in both the nervous system and
peripheral tissues of the embryonic and fetal mouse (Zhu et
al., 1998), consistent with the possibility that these recep-
tors influence fetal development. Although the prenatal
appearance of opioid receptor binding in whole brain ho-
mogenates has been detected (Rius et al., 1991), an anatomi-
cal comparison of opioid receptor proteins with the RNA
distribution during prenatal development is still lacking.
Although tissue section autoradiography with the nonspe-
cific ligand [3H]naloxone first detected opioid receptors in
the rat at e14 in the striatum and at e16 in the olfactory
cortical primordium and medial septum (Kent et al., 1981),
the prenatal distribution of specific opioid receptor sub-
types has not been explored at the protein level.
The construction of several genetic models of the opioid
system, including individual and combinatorial mutations
of each of the classical opioid receptors using gene target-
ing, has shown that mouse strains bearing one, two, or even
three null alleles of the opioid receptors show no obvious
developmental abnormalities (Simonin et al., 1998; Schul-
ler et al., 1999; Zhu et al., 1999; Gaveriaux-Ruff et al., 2001;
Clarke et al., 2002). While thorough cell counts and struc-
tural analysis of opioid receptor mutant mice are still in
progress, the grossly normal phenotype of the mutant mice
raises the question of whether the opioid receptor proteins
can be activated during development, which is critical to
determining whether the detrimental effects of opiates and
naltrexone on the developing nervous system could result
from nonspecific effects.
Conclusions drawn from gene expression or ligand bind-
ing studies examining opioid system development are lim-
ited to the extent that neither provide functional assess-
ment of receptor activity. With the advent of GTP35S
binding assays (Hilf et al., 1989; Lorenzen et al., 1993;
Traynor and Nahorski, 1995) and its adaptation to autora-
diography (Sim et al., 1995), it is now possible to determine
the anatomical pattern of opioid receptor coupling to
G-proteins in histological sections. The experiments de-
scribed below use these techniques to extend previous gene
expression and ligand binding studies and ascertain at what
stage and in which fetal brain regions the mu opioid
receptor (MOR) and delta opioid receptor (DOR) become
active and how the onset of this functional parameter of
receptor activity is related to gene activation. Such data can
determine whether the opioid receptors are active during
development and provide a clearer picture of when and
where the opioid receptors are able to influence the nervous
system and possibly other tissue types.
METHODS
Tissue Preparation
All studies were conducted in accordance with the principles and
procedures outlined in the NIH Guidelines for Care and Use of
Experimental Animals. Fresh frozen sections were used in all experi-
ments. All mice were quickly staged according to their limb bud
morphology before being embedded and frozen in OCT for cryostat
sectioning. The following age groups were examined: e11.5, e12.5,
e13.5, e15.5, e17.5, p1. Two mice were used from stage e11.5 and
e12.5, while three mice were used from stage e13.5 onward. Trans-
verse sections through the head were prepared from e11.5 embryos.
Coronal sections were prepared from the heads of embryos from all
other stages. In all cases, 20-m thick sections were cut, mounted to
TESPA subbed slides, and stored at –70°C until use.
GTP35S Autoradiography
Previous experiments (Sim and Childers, 1997) have confirmed the
specificity of DAMGO for the MOR and DPDPE for the DOR in this
paradigm. In addition, experiments performed in MOR-1 and DOR-1
KO adult membrane homogenates revealed a total lack of DAMGO-
and DPDPE-induced GTP35S binding, respectively, at the concentra-
tions used here for autoradiography, further supporting the specificity
of these drugs (data not shown). Thus, DAMGO-induced GTP35S
binding was used to assess MOR coupling, and DPDPE-induced
GTP35S binding was used to assess DOR coupling. DAMGO- and
DPDPE-induced GTP35S binding dose response curves were con-
structed in adult wild type mouse whole brain homogenates. Concen-
trations of agonist producing maximal effects in these membrane
assays were used in all autoradiography experiments.
GTP35S binding autoradiography was carried out according to
protocols developed elsewhere (Sim et al., 1995; Sim and Childers,
1997) with some modifications. Gly–gly was substituted for Tris–
HCl as a buffering agent, and DTT was added to the assay buffer.
These modifications have been shown to increase the signal-to-
noise ratio of the assay (data not shown). Triplicate sections were
first equilibrated in assay buffer (50 mM Gly–Gly, 2 mM MgCl2, 0.2
mM EGTA, 100 mM NaCl, 0.2 mM DTT) for 10 min. Sections
where then incubated in assay buffer with 2 mM GDP for 15 min.
Finally, sections were incubated in assay buffer with 2 mM GDP,
0.04 nM GTP35S, and 3 M DAMGO (to assess MOR G-protein
coupling), or 10 M DPDPE (to assess DOR G-protein coupling) for
2 h. Basal GTP binding was determined by incubating the sections
in the absence of the agonist.
Incubations in histological sections were ended by rinsing twice
with ice-cold 50 mM Gly–Gly and 0.2 mM DTT for 2 min each and
rinsing once in ice-cold distilled water for 30 s. After drying, the
slides containing the brain sections were exposed to BioMax MR
X-ray film for 5–30 days. Basal binding from all embryonic sections
was considerably less than that observed in adult mice, indicating
little spontaneous G-protein activity. This allowed for long expo-
sure times and the ability to detect the small yet significant levels
of agonist-induced GTP35S binding at earlier embryonic ages. For
reasons that remain unknown, cartilaginous structures of the head
and trunk often show high levels of basal GTP35S binding (labeled
“c” in Figs. 1A, 1B, 2A, 2B, 5E, and 5F) which are not significantly
increased by agonist treatment, indicating nonspecific binding of
the GTP35S to these areas.
The images of the individual brain section were then digitized by
using a Polaroid Digital Microscope Camera model Ie and accom-
panying software. Each embryo of each stage was analyzed densi-
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tometrically by using the NIH Image software package. The density
of GTP35S binding was converted to nCi/g using [14C] standards
enclosed in the film cassette. For each animal, in each brain region,
nCi/g values from three agonist-stimulated sections were com-
pared with three basal sections by using a t test to determine
whether significant coupling was evident. Coupling was not con-
sidered present in a brain region unless significant coupling was
seen in all embryos assessed at each stage.
RESULTS
GTP35S binding autoradiography was used to determine
at what stage and in which brain regions the MOR and DOR
are functionally active as assessed by the ability to couple
to G-proteins. As described below, there were region-
specific differences in the appearance of functional activity
by cell groups expressing either the MOR-1 or DOR-1 genes
and, in many cases, the appearance of detectable receptor
activity lagged one or more days behind the onset of gene
expression. Summaries of the temporal and spatial data for
both MOR activation and DOR activation are presented in
Tables 1 and 2, respectively, which include both semiquan-
titative and quantitative measurements. For clarity, the
results are presented by age.
e11.5
Although MOR-1 mRNA is first detected in the differen-
tiating cells of the basal ganglia at this stage (Zhu et al.,
1998), no detectable MOR receptor coupling was detected,
even after 1 month of film exposure (see Methods). No DOR
receptor coupling was seen at this stage, which is consistent
with the previously reported lack of detectable gene expres-
sion at this stage (Zhu et al., 1998).
e12.5
At e12.5, DAMGO-induced GTP35S binding was first ob-
served in the caudate-putamen (CPU) (Figs. 1A and 1B), which
coincides with the pattern of MOR-1 gene expression at this
stage. This result indicates that all factors needed for Gi/Go
coupling are present in these cells by this age. Interestingly,
while no other brain region showed receptor coupling, MOR-1
mRNA is detected in other regions, including the midbrain
and hindbrain at this age (Zhu et al., 1998), indicating that
there is a mismatch between the time of initial MOR-1 gene
expression and detectable receptor activation in these regions.
No DPDPE-induced GTP35S binding was seen at this age,
again consistent with the lack of detectable DOR-1 gene
expression at this stage (Zhu et al., 1998).
e13.5
At e13.5, the opioid receptor activation pattern is similar to
that at e12.5. DAMGO-induced GTP35S binding is again
found only in the CPU (Figs. 1C and 1D), while MOR-1 gene
expression has expanded to include midbrain, medial habe-
nula, hypothalamus, pons, medulla, and the trigeminal gan-
glia. However, expression levels in these regions are notice-
ably less than those seen in the CPU (Zhu et al., 1998). DOR-1
gene expression first appears in this stage and is confined to
the hypothalamus and pons (Zhu et al., 1998), although no
detectable DPDPE-induced GTP35S binding is present. Thus,
at this stage, there are mismatches between gene expression
and detectable receptor activation for both the MOR and DOR
in several brain regions. One mismatched region of particular
interest is the trigeminal ganglion, which shows very high
levels of MOR-1 gene expression, similar to the levels in the
CPU (Zhu et al., 1998), but no detectable GTP35S binding at
this stage. As there is detectable DAMGO-induced coupling
in the CPU at e13.5, the MOR is clearly able to influence the
function of these cells at this early stage. However, the scope
of its influence appears to be less than the gene expression
data would suggest.
e15.5
At e15.5, detectable DAMGO-induced GTP35S binding
expands significantly to several other brain regions, including
the midbrain (Figs. 2G and 2H), medial habenula (Figs. 2C and
2D), hypothalamus (Figs. 2C and 2D), pons (Figs. 2E and 2F),
and medulla (Figs. 2G and 2H). In addition, MOR-1 gene
expression levels increase in nearly all regions that previously
showed expression, although none achieve the high levels
seen in the CPU (Zhu et al., 1998). Thus, at this stage, the
expansion of MOR coupling parallels the changes in gene
expression and eliminates the mismatch between gene expres-
sion and receptor activity in many brain regions. However, a
mismatch remains in the trigeminal ganglion, which still
shows no detectable DAMGO-induced GTP35S binding, de-
spite high levels of mRNA (Figs. 2C and 2D). A similar
mismatch also remains for the DOR, as DPDPE-induced
GTP35S binding is still undetectable at this stage, while gene
expression is detectable in the pons and hypothalamus.
e17.5
The pattern of DAMGO-induced GTP35S binding at
e17.5 remains relatively unchanged compared with e15.5.
However, DAMGO-induced GTP35S binding first appears
in the olfactory bulb (OB) (Figs. 3A and 3B). As MOR-1 gene
expression also begins in the OB at this stage (Zhu et al.,
1998), the onset of MOR coupling exactly coincides with
the appearance of its mRNA in this region. In addition,
MOR coupling in the trigeminal ganglion remains unde-
tectable at this stage (Figs. 3G and 3H). DPDPE-induced
GTP35S binding is detected for the first time and is
restricted to the hypothalamus (Figs. 3H and 3I), pons (Figs.
3K and 3L), medulla (Figs. 3N and 3O), and medial habenula
(Figs. 3G and 3H). As DOR-1 gene expression is first seen in
the pons and hypothalamus at e13.5 (Zhu et al., 1998), there
is a 4-day lag between the appearance of DOR-1 mRNA and
functional activation in these regions. Interestingly, the
detection of DOR coupling in the medulla and medial
habenula occurs in the absence of detectable gene expres-
sion of the cognate receptors at this stage (Zhu et al., 1998),
which may reflect high levels of translation and coupling
from relatively low levels of DOR-1 mRNA.
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p1
The pattern of MOR receptor activation at p1 is very
similar to that seen at e17.5. The main difference is that
MOR coupling can now be localized to more discrete
regions of the midbrain, such as the substantia nigra (SN)
and the periaqueductal gray (PAG) (Figs. 4G and 4H). At this
stage, except for the trigeminal ganglia (Figs. 4E and 4F), all
regions that show MOR-1 gene expression also show MOR
receptor coupling. In addition, DOR coupling also appears
in the CPU (Figs. 5A and 5B). As DOR-1 gene expression
was first seen in the CPU at e17.5, there is a 2-day lag
between the beginning of expression and onset of receptor
function in this region.
DISCUSSION
In this study, we provide the first broad analysis of GPCR
function during embryonic development. By assessing the
developmental regulation of MOR and DOR activation, the
studies presented here extend both previous gene expres-
sion studies (Zhu et al., 1998) and more limited studies of
protein expression (Kent et al., 1981; Rius et al., 1991) by
determining the stage and brain regions where the factors
necessary for opioid receptor signal transduction appear
during ontogeny. The data show that both the MOR and
DOR are active during the prenatal and early postnatal
period and are positioned to impact the development and
function of the nervous system. Nonetheless, in nearly all
areas studied there is some mismatch between receptor
gene expression and receptor activity lasting one or more
days, suggesting that production of G-proteins or other
cofactors necessary for opioid receptor signal transduction
may also be developmentally regulated.
Summary of Receptor Activation and Comparison
with Adult Sites of Activation
The developmental pattern of MOR coupling is summa-
rized in Table 1. Functional activity is first detected at e12.5
with coupling restricted to the CPU. Activation remains
restricted to this region until e15.5, when coupling in-
creases in the CPU and expands to include the midbrain,
medial habenula, hypothalamus, pons, and medulla. At the
end of the embryonic period, the pattern of MOR coupling
closely resembles the adult pattern with some notable
FIG. 1. DAMGO-stimulated GTP35S binding in coronal sections
of e12.5 and e13.5 mouse embryos at the level of the caudate-
putamen. Sections were incubated with 2 mM GDP for 15 min,
then with 0.04 nM GTP35S, 2 mM GDP, and 3 M DAMGO for
2 h. Basal GTP35S binding was determined in the absence of
agonist. cpu, caudate-putamen; c, cartilage.
FIG. 2. DAMGO-stimulated GTP35S binding in coronal sections
of e15.5 mouse embryos. Sections were incubated with 2 mM GDP
for 15 min, then with 0.04 nM GTP35S, 2 mM GDP, and 3 M
DAMGO for 2 h. Basal GTP35S binding was determined in the
absence of agonist. Sections were taken at the level of the caudate-
putamen (A, B), hypothalamus (C, D), pons (E, F), and medulla (G,
H). cpu, caudate-putamen. hb, medial habenula; hypo, hypothala-
mus; med, medulla; V, trigeminal ganglion; c, cartilage.
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exceptions. First, except for the medial habenula, MOR
coupling, as well as MOR-1 gene expression (Zhu et al.,
1998), is entirely absent from the thalamus during the
prenatal period. In contrast, several thalamic nuclei show
considerable MOR coupling and gene expression in the
adult rodent (Mansour et al., 1994; Sim and Childers, 1997),
suggesting that although the MOR has a large role in the
functioning of these structures in the adult brain, MOR
appears to have a minimal, if any, role in their functioning
during development.
The developmental pattern of DOR coupling is summa-
rized in Table 2. In contrast to the widespread and high
levels of MOR coupling seen throughout the embryonic
period, DOR coupling appears relatively late and shows a
much more restricted distribution. DOR coupling is first
seen at e17.5 in the hypothalamus, pons, medial habenula,
and medulla. By p1, DOR activation has expanded to
include the CPU. In all of these regions, levels of coupling
were noticeably lower than that of the MOR and generally
reflected relative levels of the cognate mRNA. As with the
MOR, the pattern of receptor coupling at the end of the
prenatal period is similar to that seen in the adult, with
some exceptions. DOR coupling and DOR-1 mRNA are
absent at birth from the amygdala, which shows relatively
FIG. 3. DAMGO- and DPDPE-stimulated GTP35S binding in coronal sections of e17.5 mouse embryos. Sections were incubated with 2
mM GDP for 15 min, then with 0.04 nM GTP35S, 2 mM GDP, and 3 M DAMGO for 2 h. Basal GTP35S binding was determined in the
absence of agonist. Sections were taken at the level of the olfactory bulb (A–C), caudate-putamen (D–F), hypothalamus (G–I), pons (J–L), and
medulla (M–O). ob, olfactory bulb; cpu, caudate-putamen; hb, medial habenula; hypo, hypothalamus; med, medulla; V, trigeminal ganglion.
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high levels of DOR coupling and gene expression in the
adult rodent (Mansour et al., 1994; Sim and Childers, 1997).
Although the DOR appears to play a role in the functioning
of this region in the adult (Filliol et al., 2000), based on the
studies presented here, it has little impact on the prenatal
function of this structure.
Temporal Comparison between Opioid Receptor
Gene Expression and Activation
MOR receptor coupling first appears at e12.5 in the CPU,
which lags 1 day behind the appearance of its mRNA at
e11.5 (Zhu et al., 1998). Although only a short lag between
the onset of gene expression and receptor coupling is seen in
the CPU, 2- or 3-day lags are seen for the MOR in nearly all
other brain regions assessed, including the midbrain, me-
dial habenula, hypothalamus, and pons (Table 3). Although
rather high levels of mRNA were detected in the trigeminal
ganglion as early as e13.5 (Zhu et al., 1998), we have found
no evidence of MOR coupling during the entire fetal period,
which may limit the ability to modulate pain. In general,
the lag between the appearance of DOR-1 gene expression
and receptor activation was longer than for MOR. Although
the 1- or 2-day lag seen for the DOR in the CPU is similar
to the lag seen in that brain region for MOR, the pons and
hypothalamus showed longer delays (see Table 3). For the
DOR, a 4-day lag was found in the pons and hypothalamus,
FIG. 4. DAMGO-stimulated GTP35S binding in coronal sections
of p1 mice. Sections were incubated with 2 mM GDP for 15 min,
then with 0.04 nM GTP35S, 2 mM GDP, and 3 M DAMGO for
2 h. Basal GTP35S binding was determined in the absence of
agonist. Sections were taken at the level of the olfactory bulb (A, B),
caudate-putamen (C, D), hypothalamus (E, F), substantia nigra (G,
H), and medulla (I, J). ob, olfactory bulb; cpu, caudate-putamen; hb,
medial habenula hypo, hypothalamus; sn, substantia nigra; pag,
periaqueductal gray; med, medulla; V, trigeminal ganglion.
FIG. 5. DPDPE-stimulated GTP35S binding in coronal sections
of p1 mice. Sections were incubated with 2 mM GDP for 15 min,
then with 0.04 nM GTP35S, 2 mM GDP, and 3 M DAMGO for
2 h. Basal GTP35S binding was determined in the absence of
agonist. Sections were taken at the level of the caudate-putamen
(A, B), hypothalamus (C, D), and medulla (E, F). cpu, caudate-
putamen; hb, medial habenula; hypo, hypothalamus; med, me-
dulla; c, cartilage.
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while for the MOR, a 3-day lag was seen in the pons and a
2-day lag in the hypothalamus, indicating slower matura-
tion of DOR coupling during development.
The mismatch observed between gene expression and
receptor function could be explained in several ways: (1)
limited assay sensitivity, (2) the presence of low level of
receptor protein preceding detectable gene expression, and
(3) absence of appropriate G-proteins and other cofactors
necessary for coupling. Although a lack of sensitivity may
explain the mismatch in some regions, it is unlikely to be
responsible for the mismatch in regions with high levels of
mRNA expression, which would presumably also have high
levels of receptor. In the CPU, the high levels of MOR-1
gene expression beginning at e11.5 (Zhu et al., 1998)
quickly lead to MOR coupling at e12.5; however, clearly
this is not the case for the medulla and trigeminal ganglia.
Gene expression in both of these regions begins at e13.5
(Zhu et al., 1998) at levels similar to those seen in the CPU.
However, MOR coupling is not detected until e15.5 in the
medulla and is not detected at all during the embryonic
period in the trigeminal ganglia. Thus, in these regions, a
lack of sensitivity appears insufficient to explain the mis-
match between gene expression and receptor activity.
Moreover, the fact that DOR coupling is seen in the medial
habenula and medulla, regions that have previously been
shown to possess no detectable DOR-1 gene expression
during development (Zhu et al., 1998), provides further
evidence of the overall sensitivity of the assay.
Low assay sensitivity, however, may explain the mis-
match in other regions where levels of gene expression are
considerably lower than the CPU, such as the midbrain,
medial habenula, hypothalamus, and pons. At e12.5 and
e13.5, MOR-1 expression in these regions begins at low
levels (Zhu et al., 1998), and at this stage, no MOR coupling
can be detected, presumably because very little receptor
protein is translated from the low levels of mRNA. By
e15.5, MOR-1 gene expression has increased in these brain
regions and approaches the high levels of expression seen in
the CPU, medulla, and trigeminal ganglia (Zhu et al., 1998).
The appearance of detectable coupling at this stage most
likely reflects the increased translation of protein resulting
from higher levels of mRNA.
Alternatively, the lag between gene expression and recep-
tor coupling may be due to a mismatch between levels of
receptor protein and levels of mRNA. Subtype-specific
receptor tissue section autoradiography and immunocyto-
chemical data describing the relative abundance and ana-
tomical distribution of opioid receptor protein during pre-
natal development is lacking, so it is difficult to assess
whether a lack of translation is responsible for the mis-
match; however, some comments can be made. Ligand
binding studies indicate that MOR binding sites in brain
homogenates are first detected at e12.5, whereas DOR
binding sites are not detectable during the embryonic
period (Rius et al., 1991). Although these studies provide no
anatomic localization of the opioid receptor protein, auto-
radiography experiments using [3H]naloxone revealed opi-
oid binding sites in the rat striatum at e14 (Kent et al.,
1981), which approximately equates to e12.5–e13 in the
mouse. The relative correspondence between the ligand
binding data in the mouse and the autoradiography in the
rat with the GTP35S binding experiments presented here
provides further confidence in the sensitivity of the
GTP35S binding assays. In fact, the appearance of MOR
coupling exactly coincides with the appearance of MOR
binding sites detected in mice and naloxone binding sites in
rats. In addition, although the ligand binding studies found
no detectable DOR binding sites prior to birth, the present
study has revealed DOR coupling as early as e17.5. More-
over, DOR coupling is seen in the medial habenula and
medulla, regions that have previously been shown to pos-
sess no detectable DOR-1 gene expression during develop-
ment (Zhu et al., 1998). Taken together, these findings
support the sensitivity of the assay and indicate that this
receptor is positioned to impact embryonic development
earlier than previously suspected based on ligand binding
and gene expression studies.
Finally, the G-protein subtypes able to couple to the opioid
receptors may not be expressed or translated at the stages
when receptor mRNA is first seen. Although data describing
the prenatal developmental pattern of G-protein expression is
lacking, a recent study has explored the postnatal pattern of
G-protein subunits by using quantitative immunoblotting
(Ihnatovych et al., 2002). This study revealed clearly detect-
able amounts of Gi and Go alpha subunits in the rat cortex,
thalamus, and hippocampus in the p1 rat, and suggests that
these G subtypes are likely found in other parts of the
developing nervous system as well. Thus, it appears that the
inability of the MOR and DOR to couple to G-proteins in
certain brain regions at the later stages examined here is not
due to a lack of available and appropriate G subtypes. This
point is particularly relevant in the case of the trigeminal
ganglia. As mentioned earlier, although high levels of MOR-1
gene expression are seen in this area beginning at e13.5, no
MOR coupling is seen as late as p1, when Gi/Go is likely
present. However, the possibility still remains that the ab-
sence of other cofactors necessary for G-protein activation is
responsible for the delay in activity following the detection of
gene expression found in the trigeminal ganglia and other
brain regions.
Since GTP35S binding assays only measure receptor
coupling to Gi/Go G-proteins, the lack of coupling observed
in the trigeminal ganglia, and other regions showing high
levels of mRNA but no functional receptor activity, may
not reflect a lack of coupling but rather interaction with
other G alpha subtypes. Although the opioid receptors
predominately interact with Gi/Go, several experiments
attest to the ability of opioid receptor to couple to many
other G-protein subtypes (Sanchez-Blazquez and Garzon,
1992, 1993; Sanchez-Blazquez et al., 1993, 1995; Garzon et
al., 1994; Raffa et al., 1994; Rossi et al., 1995; Standifer et
al., 1996). Thus, transient activation of G-proteins other
than Gi/Go by the MOR and DOR could allow functional
activity and still explain the mismatch.
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Functional Implications
The present study has added a functional component to
the studies of the opioid system during embryonic develop-
ment. The results presented here describe the continued
expansion of opioid receptor coupling from midgestation on
and reveal that the changes in functional receptor activity
do not always parallel changes in receptor gene expression
or ligand binding. Thus, this study suggests that the inter-
action between opioid receptors, G-proteins, and other
factors necessary for signaling is developmentally regu-
lated. Similar regulation is seen in the cannabinoid 1
receptor (CB1) (Berrendero et al., 1998). These studies
showed that WIN-55,212–2 induced GTP35S binding in-
creased in the hippocampus in concert with increases in
mRNA level from GD16 to GD18, while WIN-55,212–2
induced GTP35S binding disappeared in the cortex despite an
increase in mRNA in that same brain region. However, the
scope of CB1 receptor regulation during development is diffi-
cult to assess because only a relatively limited period of
development was investigated and the earliest stages of func-
tional activity were not determined. By assessing opioid re-
ceptor function from their earliest detectable activation, we
have shown that developmental regulation of GPCR is more
widespread both temporally and spatially than suggested by
the studies investigating the CB1 receptor.
The data outlined here also provide additional evidence
that both the MOR and DOR can contribute to the adverse
outcomes that follow in utero exposure to opiates. It has
TABLE 1
Relative Amount of MOR Coupling during Development
OB CPU Hypo MHb MB pons Med
Rel
Amt
nCi/g
SEM
Rel
Amt
nCi/g
SEM
Rel
Amt
nCi/g
SEM
Rel
Amt
nCi/g
SEM
Rel
Amt
nCi/g
SEM
Rel
Amt
nCi/g
SEM
Rel
Amt
nCi/g
SEM
e12.5 — —  46  9 — — — — — — — — — —
e13.5 — —  46  7 — — — — — — — — — —
e15.5 — —  64  3  28  3  47  5  19  2  28  5  30  3
e17.5  40  3  161  31  73  11  71  2  116  21  142  21  172  5
p1  38  7  189  19  76  3  72  20  51  5  100  7  117  10
Note. Sections were incubated with 2 mM GDP for 15 min, then with 0.04 nM GTP35S, 2 mM GDP, and 3M DAMGO for 2 h. Basal GTP35S
binding was determined in the absence of agonist. Each embryo of each stage was analyzed densitometrically by using the NIH Image software
package. The density of GTP35S binding was converted to nCi/g by using [14C] standards enclosed in the film cassette. For each animal, in each
brain region, nCi/g values from three agonist-stimulated sections were compared with three basal sections by using a t test to determine whether
significant coupling was evident. Coupling was not considered present in a brain region unless significant coupling was seen in all embryos
assessed at each stage. The nCi/g values are expressed as mean  standard error of the mean, and the relative amounts scale is based on the
following measurements: , no significant coupling; , 50 nCi/g [14C]; , 51–100 nCi/g [14C]; , 101–150 nCi/g [14C]; , 151–200
nCi/g [14C]. OB, olfactory bulb; CPU caudate-putamen; Hypo, hypothalamus; MHb, medial habenula; MB, midbrain; Med, medulla.
TABLE 2
Relative Amount of DOR Coupling during Development
OB CPU Hypo MHb MB pons Med
Rel
Amt
nCi/g
SEM
Rel
Amt
nCi/g
SEM
Rel
Amt
nCi/g
SEM
Rel
Amt
nCi/g
SEM
Rel
Amt
nCi/g
SEM
Rel
Amt
nCi/g
SEM
Rel
Amt
nCi/g
SEM
e12.5 — — — — — — — — — — — — — —
e13.5 — — — — — — — — — — — — — —
e15.5 — — — — — — — — — — — — — —
e17.5 — — — —  55  4  44  20 — —  80  5  72  5
p1 — —  44  12  44  2  98  23 — —  74  12  53  1
Note. Sections were incubated with 2 mM GDP for 15 min, then with 0.04 nM GTP35S, 2 mM GDP, and 3 M DPDPE for 2 h. Basal GTP35S
binding was determined in the absence of agonist. Each embryo of each stage was analyzed densitometrically by using the NIH Image software
package. The density of GTP35S binding was converted to nCi/g by using [14C] standards enclosed in the film cassette. For each animal, in each
brain region, nCi/g values from three agonist-stimulated sections were compared with three basal sections by using a t test to determine whether
significant coupling was evident. Coupling was not considered present in a brain region unless significant coupling was seen in all embryos
assessed at each stage. The nCi/g values are expressed as mean  standard error of the mean, and the relative amounts scale is based on the
following measurements: , no significant coupling; , 50 nCi/g [14C]; , 51–100 nCi/g [14C]; , 101–150 nCi/g [14C]; , 151–200
nCi/g [14C]. OB, olfactory bulb; CPU caudate-putamen; Hypo, hypothalamus; MHb, medial habenula; MB, midbrain; Med, medulla.
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been shown that in utero exposure to morphine desensi-
tizes the MOR in several medullary brain regions involved
in respiration (Matsuda and Olsen, 2001). Since exogenous
opiate drugs and endogenous opioid peptides produce respi-
ratory depression, it was proposed that the MOR uncou-
pling found in the medulla is responsible for the hyperven-
tilation seen in opiate-exposed pups. The CPU, shown in
the present study to exhibit both DOR and MOR coupling
during development, is involved in many facets of motor
behavior (Lucien and Crutcher, 1991). Thus, perturbation of
normal opioid signaling in this region during development
by exogenous opiates could be responsible for the motor
deficits seen in both rodents (Zagon and McLaughlin, 1978;
Zagon et al., 1979a; McLaughlin et al., 1997a) and humans
(Bunikowski et al., 1998) exposed to opiates in utero.
Further investigation is warranted to determine whether
alterations in opioid receptor coupling in these and other
regions discussed here are involved in the adverse effects of
pre- and postnatal opiate exposure.
In conclusion, the results of this study outline for the first
time the prenatal developmental pattern of opioid receptor
activation, revealing the spatial and temporal patterns in
which the necessary factors are assembled that allow the
MOR and DOR to couple to G-proteins. Since receptor
activity in some cases significantly lags behind the first
appearance of opioid receptor mRNA, these findings sug-
gest an intricate interaction between receptor expression,
translation, and the availability of G-proteins and other
signaling cofactors to produce functional signaling sys-
tems during development. Moreover, the demonstration
of receptor activity during gestation indicates that the
lack of a developmental phenotype in opioid receptor
knockout mice is not due to a lack of receptor function
during development. Instead, both the MOR and DOR
have the capacity to influence nervous system function
during both normal development and after exposure to
exogenous opiate drugs.
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